Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Hutchmed (HCM)

Price 310.00p on 04-10-2024 at 16:30:00
Change 12.00p 4.03%
Buy 311.00p
Sell 308.00p
Buy / Sell HCM Shares
Last Trade: Unknown 25,000.00 at 318.00p
Day's Volume: 1,761,486
Last Close: 310.00p
Open: 307.00p
ISIN: KYG4672N1198
Day's Range 307.00p - 327.00p
52wk Range: 190.40p - 353.00p
Market Capitalisation: £2,649m
VWAP: 316.3314p
Shares in Issue: 854m

Recent Trades History Hutchmed (HCM)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Unknown* 25,000 318.00p Negotiated Trade
15:21:53 - 04-Oct-24
Unknown* 49,382 311.00p Negotiated Trade
12:35:28 - 04-Oct-24
Sell* 52 310.00p Automatic Execution
16:39:10 - 04-Oct-24
Sell* 1,000 310.00p Automatic Execution
16:39:05 - 04-Oct-24
Sell* 688 310.00p Automatic Execution
16:38:56 - 04-Oct-24
Buy* 8,260 310.00p Automatic Execution
16:38:11 - 04-Oct-24
Buy* 35,000 310.00p Suspected BUY Trade
16:36:54 - 04-Oct-24
Buy* 10,000 310.00p Automatic Execution
16:36:20 - 04-Oct-24
Buy* 28,987 310.00p Suspected BUY Trade
16:35:00 - 04-Oct-24
Buy* 500 311.00p Automatic Execution
16:23:40 - 04-Oct-24

Share Price History for Hutchmed

Time period:
to
Date Open High Low Close Volume

Share News for Hutchmed

Takeda Pharmaceutical says Fruzaqla cancer drug gets Japan backing

24th Sep 2024 08:49

(Alliance News) - Takeda Pharmaceutical Co Ltd on Tuesday said it landed an approval for its Fruzaqla drug in Japan. Read More

Hutchmed "disappointed" as it withdraws fruquintinib application

30th Aug 2024 12:24

(Alliance News) - Hutchmed (China) Ltd announced on Friday that it has voluntarily withdrawn its supplemental new drug application for fruquintinib in China. Read More

Hutchmed confident of full year guidance for oncology and immunology

31st Jul 2024 14:41

(Alliance News) - Hutchmed (China) Limited on Wednesday said it remains on track to meet full year guidance for its oncology/immunology business, despite a fall in revenue. Read More

UK earnings, trading statements calendar - next 7 days

24th Jul 2024 14:45

Read More

IN BRIEF: Hutchmed's tazemetostat given priority review in China

5th Jul 2024 19:08

Hutchmed (China) Ltd - Hong Kong-based pharmaceutical company - Says new drug application for tazemetostat given priority review by the China National Medical Products Administration. Tazemetostat was developed by Epizyme Inc for the treatment of adult patients with relapsed or refractory follicular lymphoma. Drug was given accelerated approval in the US for certain patients with R/R FL and certain patients with advanced epithelioid sarcoma. Also approved in Japan for certain patients with R/R FL. The decision was supported by a phase II bridging study in China, and clinical studies conducted by Epizyme outside China. Tazemetostat was approved for use in Macau in 2023 and Hong Kong in 2024. Read More

FTSE 100 Latest
Value8,280.63
Change-1.89

Login to your account

Forgot Password?

Not Registered